Stockscreener 앱 받기
4.945
0.20%
-0.005
전일 마감가:
$4.95
열려 있는:
$4.95
하루 거래량:
359.32K
Relative Volume:
0.50
시가총액:
$297.81M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-6.5933
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
-5.54%
1개월 성능:
-6.08%
6개월 성능:
+128.70%
1년 성능:
+5.11%
1일 변동 폭
$4.795
$4.99
1주일 범위
$4.795
$5.35
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.94 | 297.81M | 0 | -44.80M | -30.67M | -0.75 |
|
ARGX
Argen X Se Adr
|
922.01 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.58 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.15 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
365.33 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.19 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Live market analysis of Aldeyra Therapeutics Inc.Treasury Yields & Fast Gaining Stock Reports - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsFed Meeting & Safe Capital Growth Stock Tips - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zone2025 Price Action Summary & Low Drawdown Trading Strategies - newser.com
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 AllTime Highs & Growth Focused Entry Reports - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
What to expect from Aldeyra Therapeutics Inc. in the next 30 daysTrade Ideas & Weekly Top Gainers Trade List - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.2025 Price Targets & Smart Money Movement Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryLayoff News & Stock Timing and Entry Methods - newser.com
Is Aldeyra Therapeutics Inc. stock resilient to inflation2025 Market Sentiment & Accurate Intraday Trade Tips - Fundação Cultural do Pará
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableQuarterly Market Summary & Pattern Based Trade Signal System - Fundação Cultural do Pará
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research and Development Webcast - MarketScreener
Is Aldeyra Therapeutics Inc. stock affected by interest rate hikesPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Aldeyra expands RASP platform to include neuroinflammatory diseases By Investing.com - Investing.com Nigeria
Understanding Aldeyra Therapeutics Inc.’s price movementQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Automated trading signals detected on Aldeyra Therapeutics Inc.Dip Buying & Stepwise Trade Execution Plans - newser.com
Analyzing net buyer seller activity in Aldeyra Therapeutics Inc.Risk Management & Real-Time Buy Signal Alerts - newser.com
ALDX: ADX-248 advances in CNS and immune diseases as reproxalap nears FDA approval, with strong financials - TradingView
Published on: 2025-11-13 12:25:09 - newser.com
Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases - GuruFocus
Aldeyra Therapeutics announces expansion of rasp platform - MarketScreener
Aldeyra expands RASP platform to include neuroinflammatory diseases - Investing.com India
Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap - TradingView
Key FDA Verdict Looms for Aldeyra’s Lead Drug Candidate - AD HOC NEWS
Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aldeyra Therapeutics Inc 주식 (ALDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
0.01%
0.47%
자본화:
|
볼륨(24시간):